Global Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Vaxcyte

Market Cap: US$4.1b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

Arterra Bioscience

Market Cap: €15.2m

A research-based biotech company, engages in the research and development of various ingredients and natural solutions.

Pacira BioSciences

Market Cap: US$1.2b

Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.

AcuCort

Market Cap: SEK 207.8m

Develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions.

Onco-Innovations

Market Cap: CA$78.0m

A pre-clinical stage biotechnology company, develops drug candidates for cancer treatments.

Stevanato Group

Market Cap: US$6.8b

Engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.

Synlogic

Market Cap: US$12.6m

A biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.

SpringWorks Therapeutics

Market Cap: US$3.5b

A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.

Qiagen

Market Cap: US$9.3b

Provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.

Kyverna Therapeutics

Market Cap: US$89.5m

Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.

XORTX Therapeutics

Market Cap: CA$5.5m

A late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease.

RenovoRx

Market Cap: US$45.3m

A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.

ProKidney

Market Cap: US$236.6m

A clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.

PCI Biotech Holding

Market Cap: NOK 64.2m

A biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform.

MacroGenics

Market Cap: US$100.3m

A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.

GH Research

Market Cap: US$725.7m

Together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States.

Lytix Biopharma

Market Cap: NOK 573.4m

A clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States.

Anbio Biotechnology

Market Cap: US$330.9m

Provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.

Niagen Bioscience

Market Cap: US$862.8m

Operates as a bioscience company engages in developing healthy aging products.

Aldeyra Therapeutics

Market Cap: US$144.9m

A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.

Sagimet Biosciences

Market Cap: US$110.4m

A clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.

Dianthus Therapeutics

Market Cap: US$619.7m

A clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.

High Tide

Market Cap: CA$269.5m

Engages in the cannabis retail business in Canada, the United States, and internationally.

Medicure

Market Cap: CA$10.4m

A biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States.

Tchaikapharma High Quality Medicines AD

Market Cap: лв1.6b

Engages in the development and manufacture of generic and in-licensed medicines in Bulgaria.

Blau Farmacêutica

Market Cap: R$2.5b

A pharmaceutical company provides high-complpexity drugs in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States.

PharmaCyte Biotech

Market Cap: US$7.1m

A biotechnology company, develops and commercializes cellular therapies for cancer in the United States.

Trevi Therapeutics

Market Cap: US$660.3m

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough conditions targeting the central and peripheral nervous systems.

Revolution Medicines

Market Cap: US$7.4b

A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.

Tourmaline Bio

Market Cap: US$427.2m

Operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases.

Exicure

Market Cap: US$64.6m

Does not have significant operations.

HilleVax

Market Cap: US$96.7m

A clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States.

Atossa Therapeutics

Market Cap: US$127.1m

Operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.

Corcept Therapeutics

Market Cap: US$7.9b

Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

Intellia Therapeutics

Market Cap: US$938.5m

A clinical-stage gene editing company, focuses on the development of curative genome editing treatments.

ACADIA Pharmaceuticals

Market Cap: US$3.7b

A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.